Skip to main content
. 2016 Dec 16;8(6):9251–9266. doi: 10.18632/oncotarget.14002

Figure 3. Effects of LY3009120 on cell cycle and apoptosis.

Figure 3

(A) Representative experiment of CRC cell lines treated with either DMSO or LY3009120 (0.5 μM) for the times indicated, fixed and stained with propidium iodide and analyzed for cell cycle by flow cytometry. (B) CRC cell lines were treated with increasing concentrations of LY3009120, fixed at 24 or 48 hrs (left and right panels respectively) and stained for immunofluorescence with Click-iT® EdU and antibodies against pERK1/2 T202/Y204 and pHH3 S10 as indicated. The average intensity of the signal for each analyte was measured by HCI. The data are representative of two independent experiments each conducted in triplicate technical replicates, with results plotted as percent of DMSO-treated cells. (C) Cells were treated with increasing concentrations of LY3009120 and fixed at 48 hrs post-treatment. Cells were stained for immunofluorescence analysis with antibodies against the proteins indicated and the average intensity of the signal for each analyte was measured by HCI. Results are plotted as percent of DMSO-treated cells and are representative of two independent experiments.